MX2021015783A - Metodos de tratamiento de enfermedades colestaticas. - Google Patents
Metodos de tratamiento de enfermedades colestaticas.Info
- Publication number
- MX2021015783A MX2021015783A MX2021015783A MX2021015783A MX2021015783A MX 2021015783 A MX2021015783 A MX 2021015783A MX 2021015783 A MX2021015783 A MX 2021015783A MX 2021015783 A MX2021015783 A MX 2021015783A MX 2021015783 A MX2021015783 A MX 2021015783A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- cholestatic diseases
- diseases
- cholestatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al elafibranor o una sal farmacéuticamente aceptable del mismo, para usarse en el tratamiento de colangitis esclerosante primaria (CEP), en una modalidad particular de la invención el elafibranor está adaptado para ser administrable en una dosis de entre 0.01 mg y 1 g, preferiblemente de 1 mg a 150 mg y más preferiblemente de 70 mg a 130 mg; en otra modalidad el elafibranor está adaptado para ser administrable en una dosis de 80 mg o en una dosis de 120 mg. Otras modalidades específicas de la presente solicitud se refieren al elafibranor para usarse en el tratamiento de colangitis esclerosante primaria (CEP), en donde el elafibranor está en forma de una composición farmacéutica, en donde la composición se formula en forma de suspensiones inyectables, geles, aceites, píldoras, supositorios, polvos, cápsulas de gel, cápsulas, aerosoles o medios de formas galénicas o dispositivos que aseguran una liberación prolongada y/o lenta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305381 | 2016-03-31 | ||
| PCT/EP2017/057634 WO2017167935A1 (en) | 2016-03-31 | 2017-03-30 | Methods of treatment of cholestatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015783A true MX2021015783A (es) | 2022-12-09 |
Family
ID=55661352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015783A MX2021015783A (es) | 2016-03-31 | 2017-03-30 | Metodos de tratamiento de enfermedades colestaticas. |
| MX2018011738A MX388863B (es) | 2016-03-31 | 2017-03-30 | Metodos de tratamiento de enfermedades colestaticas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011738A MX388863B (es) | 2016-03-31 | 2017-03-30 | Metodos de tratamiento de enfermedades colestaticas. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11185519B2 (es) |
| EP (3) | EP3435996B1 (es) |
| JP (1) | JP7010836B2 (es) |
| KR (1) | KR102338085B1 (es) |
| CN (2) | CN114796237B (es) |
| AU (1) | AU2017242819B2 (es) |
| CA (1) | CA3018132C (es) |
| EA (1) | EA038386B1 (es) |
| ES (1) | ES3030999T3 (es) |
| FI (1) | FI3435996T3 (es) |
| IL (2) | IL311687A (es) |
| LT (1) | LT3435996T (es) |
| MX (2) | MX2021015783A (es) |
| NZ (1) | NZ785185A (es) |
| PH (1) | PH12018502056B1 (es) |
| PT (1) | PT3435996T (es) |
| SG (1) | SG11201808222RA (es) |
| SM (1) | SMT202500241T1 (es) |
| WO (1) | WO2017167935A1 (es) |
| ZA (1) | ZA201807084B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020183388A1 (en) * | 2019-03-13 | 2020-09-17 | Novartis Ag | Pharmaceutical composition |
| KR102051030B1 (ko) | 2011-10-28 | 2019-12-02 | 루메나 파마수티컬즈, 인코포레이티드 | 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제 |
| CN107375291A (zh) | 2011-10-28 | 2017-11-24 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| CA3051977A1 (en) * | 2017-02-24 | 2018-08-30 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2019099761A1 (en) * | 2017-11-16 | 2019-05-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| WO2019186410A1 (en) * | 2018-03-27 | 2019-10-03 | Lupin Limited | Solid forms of elafibranor and processes thereof |
| WO2020074737A1 (en) * | 2018-10-11 | 2020-04-16 | Centre National De La Recherche Scientifique | Treatment of diseases associated with biliary system destruction |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| HRP20240801T1 (hr) | 2019-02-12 | 2024-09-27 | Mirum Pharmaceuticals, Inc. | Postupci za povećanje rasta kod pedijatrijskih pojedinaca koji imaju kolestatsku bolest jetre |
| MA55588A (fr) * | 2019-04-09 | 2022-02-16 | Genfit | Combinaison de nitazoxanide et d'elafibranor pour le traitement de maladies immunitaires ou d'une inflammation |
| CN110548118B (zh) * | 2019-10-21 | 2021-09-14 | 江苏省中医院 | 一种具有防治原发性胆汁性胆管炎的中药复方及其制备方法与应用 |
| CA3163583A1 (en) * | 2020-02-10 | 2021-08-19 | Genfit | Polymorphs of elafibranor |
| CN114980876A (zh) * | 2020-02-10 | 2022-08-30 | 基恩菲特公司 | 用艾拉菲诺治疗原发性胆汁性胆管炎 |
| KR20230011958A (ko) * | 2020-05-18 | 2023-01-25 | 장피트 | 원발성 경화성 담관염의 치료를 위한 엘라피브라노 |
| IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | Polymorphs of an ssao inhibitor |
| WO2022043367A1 (en) * | 2020-08-26 | 2022-03-03 | Genfit | Compositions and methods for the treatment of primary biliary cholangitis |
| IL316411A (en) * | 2022-05-19 | 2024-12-01 | Tyra Biosciences Inc | Therapies with PPAR agonists and FGFR4 inhibitors |
| US12296050B2 (en) | 2023-10-05 | 2025-05-13 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
| WO2025075624A1 (en) * | 2023-10-05 | 2025-04-10 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) * | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| US20070197606A1 (en) * | 2006-02-22 | 2007-08-23 | Burczynski Frank J | Use of ppar agonists as anti-oxidants |
| ES2681794T3 (es) * | 2009-11-26 | 2018-09-17 | Genfit | Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
| BR112017016766B1 (pt) * | 2015-02-06 | 2023-11-07 | Intercept Pharmaceuticals, Inc | Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática |
| CA3051977A1 (en) * | 2017-02-24 | 2018-08-30 | Genfit | Pharmaceutical compositions for combination therapy |
-
2017
- 2017-03-30 FI FIEP17713332.9T patent/FI3435996T3/fi active
- 2017-03-30 MX MX2021015783A patent/MX2021015783A/es unknown
- 2017-03-30 ES ES17713332T patent/ES3030999T3/es active Active
- 2017-03-30 EA EA201892202A patent/EA038386B1/ru unknown
- 2017-03-30 KR KR1020187031600A patent/KR102338085B1/ko active Active
- 2017-03-30 CA CA3018132A patent/CA3018132C/en active Active
- 2017-03-30 IL IL311687A patent/IL311687A/en unknown
- 2017-03-30 SM SM20250241T patent/SMT202500241T1/it unknown
- 2017-03-30 IL IL261935A patent/IL261935B2/en unknown
- 2017-03-30 EP EP17713332.9A patent/EP3435996B1/en active Active
- 2017-03-30 SG SG11201808222RA patent/SG11201808222RA/en unknown
- 2017-03-30 AU AU2017242819A patent/AU2017242819B2/en active Active
- 2017-03-30 LT LTEPPCT/EP2017/057634T patent/LT3435996T/lt unknown
- 2017-03-30 EP EP23175851.7A patent/EP4233910A3/en not_active Withdrawn
- 2017-03-30 MX MX2018011738A patent/MX388863B/es unknown
- 2017-03-30 US US16/090,415 patent/US11185519B2/en active Active
- 2017-03-30 CN CN202210467808.5A patent/CN114796237B/zh active Active
- 2017-03-30 NZ NZ785185A patent/NZ785185A/en unknown
- 2017-03-30 CN CN201780020144.5A patent/CN109152756B/zh active Active
- 2017-03-30 JP JP2018550793A patent/JP7010836B2/ja active Active
- 2017-03-30 PT PT177133329T patent/PT3435996T/pt unknown
- 2017-03-30 PH PH1/2018/502056A patent/PH12018502056B1/en unknown
- 2017-03-30 WO PCT/EP2017/057634 patent/WO2017167935A1/en active IP Right Grant
- 2017-03-30 EP EP25170190.0A patent/EP4559481A2/en active Pending
-
2018
- 2018-10-24 ZA ZA2018/07084A patent/ZA201807084B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502056A1 (en) | Methods of treatment of cholestatic diseases | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| TW201613901A (en) | New compounds | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| HK1220155A1 (zh) | 治療癌症的方法 | |
| NZ738218A (en) | Gls1 inhibitors for treating disease | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| PH12015501566A1 (en) | Methods of treatment of fibrosis and cancers | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| PH12017501872A1 (en) | Methods of treating diseases | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |